As has been the case with HIV it is possible that no successful vaccine will be developed, but similarly treatments may be developed such that hospitalization can be avoided.

In this section we highlight what we believe are among the most promising therapies being offered today.  Members should submit advancements for review and possible inclusion in this section.  SUBMIT


The MATH+ Hospital Treatment Protocol for COVID-19 is intended for use in the hospitalized patient, with an emphasis on early initiation — as soon as the patient develops a need for supplemental oxygen.  MATH+ hospitals have been reporting hospital mortality between 4% and 10%  as opposed to approximately 23%.  MORE >


A paper authored by 23 physicians concludes  that it is conceivable that some if not a majority of hospitalizations could be avoided with a treat-at-home first approach with appropriate telemedicine monitoring and access to oxygen and therapeutics. An algorithm based on age and comorbidities that enables monitoring and treated at home during self-isolation to reduce risks of hospitalization and death. MORE > 


At a single institution, consecutive case series of 25 COVID-19 hospitalized patients treated with as adjuvant therapy.  All 25 patients in the series survived hospitalized COVID-19 without mechanical ventilation or renal replacement therapy (RRT) and were discharged on room air within a median of 3 days (range 1-16 days).  In this series, combined treatment with in an adjuvant setting was associated with 100% survival and improved radiographic outcomes, as well as statistically significant improvements in clinical, biomarker, and renal function measurements. The 9 patients with extremely high LDH (>365, Wuhan model prediction of 98% mortality) survived and were discharged on room air.  MORE >

NOTE: Additional information about each is available for members only who have signed agreement regarding use and distribution of information.

Therapies for treat COVID-19 can be placed into two broad categories:

• Therapeutics that treat viral infection.
• Therapeutics that mitigate COVID-19 complications and/or comorbid conditions.


  • Regeneron Pharmaceuticals: Regeneron is a biotechnology and pharmaceutical company founded in 1988. Their potential COVID-19 treatment drug, Kevzara, is an interleukin-6 (IL-6) inhibitor and was originally indicated for rheumatoid arthritis treatment. As of April 11, 2020, Regeneron had launched a Phase II/III trial with 300 patients. In the past six months, Regeneron stocks (NASDAQ: REGN) have increased from $376.51 to $620.35, a 64.76% increase, and Regeneron’s market cap has increased from $41.41 B to $61.29 B since December 31st, 2019. (Stock Price as of Sept 8th. $560.65)
  • Gilead Sciences: Gilead Biosciences is a biopharmaceutical company founded in 198753. Their COVID-19 candidate drug, Remdesivir, was originally created as a therapeutic for Ebola patients. Remdesivir has undergone several late-stage trials in Asia, and one trial performed by US authorities. Recent findings are mixed as to the beneficial effects of Remdesivir for COVID-19 treatment. Gilead stocks (NASDAQ: GILD) have increased from $66.72 to $75.02 in the past six months, an increase of 12.44%, and Gilead’s market cap has increased from $82.26 B to $94.92 B since December 31st, 2019. (Stock Price as of Sept 8th. $64.64.)